clinical trial · NCT07455136
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury
Hoffmann-La Roche·—·recruiting·n = 2,000
Traumatic Brain InjuryBlood sample collection
brief summary
The study is intended to cover two purposes: first, to develop a blood-based biomarker test for aiding the diagnosis of traumatic brain injury (TBI) in adult participants and for prognosis of outcome of TBI (CLIN12.1); and second, for monitoring the development of secondary events in adult participants diagnosed with TBI (CLIN12.2).
started
Feb 9, 2026
primary completion
Mar 31, 2028
completion
May 31, 2028
last updated
Apr 3, 2026
official title
A Multicenter Prospective Study to Develop a Blood-based Biomarker Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adult Subjects (CLIN12.1) and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury (CLIN12.2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol